LOGIN  |  REGISTER
C4 Therapeutics

Latest Artificial Intelligence (AI) News

ImmunoPrecise Antibodies Validates LENSai Epitope Mapping Platform Across Broad Range of Unseen Therapeutic Targets Beyond Training Data

July 3
Last Trade: 1.58 0.27 20.61

New benchmark confirms LENSai’s ability to accurately predict binding on 17 previously unseen antibody-antigen complexes, achieving near-crystallography precision without prior training data. AUSTIN, Texas / Jul 03, 2025 / Business Wire / ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), an AI-powered biotherapeutics company, today announced a new validation study supporting the generalizability of its proprietary...Read more


Renovaro Launches AI-Based Neurotoxin Countermeasure Initiative Addressing Emerging National Security Needs

June 30
Last Trade: 0.29 0.0011 0.38

LOS ANGELES, CALIFORNIA / ACCESS Newswire / June 30, 2025 / Renovaro Inc.'s (NASDAQ:RENB) wholly owned subsidiary BioSymetrics has unveiled a proprietary AI-based zebrafish screening platform designed to rapidly identify medical countermeasures for neurotoxic chemical agents, including weaponized substances like Sarin. The platform has been integrated into Renovaro's Defense Countermeasures Program, marking a strategic entry into the...Read more


NetraMark's AI Significantly Outperforms ChatGPT, DeepSeek and Traditional Machine Learning in Clinical Trial Subpopulation Discovery, Offers New Path for Trial Success

June 23
Last Trade: 1.32 -0.03 -2.22

TORONTO, June 23, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is transforming clinical trials has released a new preprint on arXiv demonstrating that its flagship AI platform, NetraAI, has substantially outperformed leading large language models, DeepSeek and ChatGPT. NetraAI also outperformed traditional...Read more


Ekso Bionics’ Acceptance into NVIDIA Connect Program Bears Early Fruit

June 18
Last Trade: 3.24 -0.04 -1.22

AI voice agent for user interface being designed to support exoskeleton device operation, motivation, training, and safety First proof-of-concept demonstration comes just over a month after Company announced its acceptance into the NVIDIA Connect Program SAN RAFAEL, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (“Ekso Bionics” or the “Company”), an industry leader in exoskeleton technology for...Read more


Lisata Therapeutics and GATC Health Expand Relationship to Advance AI-Driven Drug Discovery and Development

June 17
Last Trade: 2.58 -0.04 -1.53

Expanded alliance combines Lisata’s drug development expertise with GATC’s AI-powered Multiomics Advanced Technology® platform to accelerate and improve success rates of next-generation drug development Lisata to lead development efforts to advance GATC’s AI-discovered therapeutic for opioid use disorder into human clinical trials early in 2026 BASKING RIDGE, N.J. and IRVINE, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- Lisata...Read more


Predictive Oncology Develops Functional 3D Organoid Models Exclusively for Labcorp

June 12
Last Trade: 0.83 -0.02 -2.36

Models provide highly relevant species-specific data, predict in vivo drug clearance/transport, and support preclinical analysis of cancer therapies PITTSBURGH, June 12, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, announced today the company has successfully developed 3D organoid models exclusively for Labcorp (NYSE: LH), a global leader of innovative and comprehensive...Read more


AI-Designed GLP-1 Peptides from ImmunoPrecise Antibodies Surpass Semaglutide in Receptor Activation Studies

June 12
Last Trade: 1.58 0.27 20.61

Breakthrough in AI-powered drug discovery validates HYFT™-driven peptide design, with broad potential across multiple therapeutic areas AUSTIN, Texas / Jun 12, 2025 / Business Wire / ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA), a leader in AI-powered drug discovery and biotherapeutics, today announced compelling in vitro results demonstrating that its artificial intelligence (AI)-designed GLP-1 receptor agonist (GLP-1RA) peptide...Read more


Cigna Healthcare Unveils Industry-Leading AI-Powered Digital Tools for a Simple and Reliable Customer Experience

June 12
Last Trade: 312.05 -7.70 -2.41

New features blend innovation, responsible AI, and human interactions to better support customers in their health care journeys As new data show 4 out of 5 U.S. adults don't feel confident in their knowledge of health insurance benefits, new digital tools use clear, conversational language to boost understanding and help customers get more out of their coverage BLOOMFIELD, Conn., June 12, 2025 /PRNewswire/ -- Cigna Healthcare, the...Read more


IQVIA Launches New AI Agents for Life Sciences and Healthcare

June 11
Last Trade: 162.38 -1.86 -1.13

RESEARCH TRIANGLE PARK, N.C. / Jun 11, 2025 / Business Wire / IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, unveils AI agents at GTC Paris. IQVIA’s new custom-built AI agents using NVIDIA technology are designed to enhance workflows and accelerate insights for life sciences. These live applications of agentic...Read more


HEALWELL AI Leverages Orion Health to Power Entry into US Market

June 11
Last Trade: 1.31 -0.01 -0.76

HEALWELL launches in the U.S. market a suite of AI enabled tools to complement Orion Health's established software offerings in the U.S. This will bring together HEALWELLs globally validated AI capabilities with Orion Health's best-in-class health data infrastructure software creating a unique offering for the U.S. market. This U.S. market launch leverages Orion Health's deep U.S. sector experience, existing U.S. footprint and...Read more


MIT and Recursion Release Boltz-2: Next Generation AI Model to Predict Binding Affinity at Unprecedented Speed, Scale, and Accuracy

June 6
Last Trade: 4.92 -0.35 -6.64

Boltz-2 is the first biomolecular co-folding model to combine structure and binding affinity prediction, approaching the accuracy of physics-based free energy perturbation (FEP) calculations but at speeds up to 1000x faster in standard benchmarks The development of this open source model for academic and commercial use was a collaborative effort, combining MIT’s deep academic expertise with Recursion's AI research and...Read more


ImmunoPrecise Antibodies Announces AI-Driven Breakthrough in Universal Dengue Vaccine Discovery

June 5
Last Trade: 1.58 0.27 20.61

LENSai™ powered by HYFT® technology Identifies a single multi-factorial target conserved across all dengue serotypes. AUSTIN, Texas / Jun 05, 2025 / Business Wire / ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ:IPA) a leader in AI-driven biotherapeutics, announces discovery of a highly conserved epitope across all four dengue virus serotypes using its proprietary LENSai™ platform powered by their patented HYFT® technology. This...Read more


RadNet Acquires See-Mode Technologies for Innovation in AI-Powered Ultrasound Diagnostics

June 4
Last Trade: 55.52 -0.69 -1.23

See-Mode’s commercially available AI-powered ultrasound detection, characterization, and reporting solutions for thyroid and breast will be integrated into RadNet’s DeepHealth population health solutions Real-world deployment of See-Mode’s FDA-approved thyroid ultrasound solution at RadNet imaging centers demonstrates improved workflow efficiency and enhanced diagnostic accuracy The acquisition positions RadNet at the forefront of AI...Read more


Perimeter Medical Imaging AI Launches OCT-Tissue Registry to Power AI and Imaging Innovation

June 4
Last Trade: 0.27 0.005 1.92

Registry aims to collect thousands of images and data from surgeries performed nationwide TORONTO and DALLAS, June 4, 2025 /CNW/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PYNKF) ("Perimeter" or the "Company") announced today that it has launched the OCT-Tissue Surveillance Registry, a database that aims to collect thousands of images and data from surgical procedures performed using the company's imaging technology....Read more


MindBio Therapeutics: Booze AI, the World's First Voice-Activated AI Powered Blood Alcohol Estimator over a Smartphone, Launches in Silicon Valley

June 3
Last Trade: 0.005 0.00 0.00

MindBio debuts app.booze-ai.com to investors in Silicon Valley Vancouver, British Columbia – TheNewswire - June 3, 2025 – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6), (“MindBio”), (the “Company”), a clinical-stage biopharma/biotechnology company has today launched Booze AI, in Silicon Valley, debuting the world’s first AI-driven, voice-activated blood alcohol concentration (BAC) estimator for use on smartphones, tablets and...Read more


Tempus AI Introduces Fuses, A Program Designed to Transform Therapeutic Research and Build the Largest Diagnostic Platform Using its Novel Foundation Model

May 31
Last Trade: 58.10 -2.88 -4.72

The initiative will apply its massive, multimodal dataset to build models that aim to improve diagnostic, prognostic, and predictive modeling CHICAGO / May 31, 2025 / Business Wire / Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the launch of its Fuses program. This initiative will harness Tempus’ proprietary dataset to generate valuable...Read more


Illumina unveils PromoterAI, a groundbreaking algorithm to accelerate insights for rare disease diagnosis

May 29
Last Trade: 97.20 -3.61 -3.58

New AI algorithm accurately deciphers pathogenic regulatory genetic variants in the noncoding regions of the human genome at scale for the first time SAN DIEGO, May 29, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) today unveiled PromoterAI, a new AI algorithm that accurately deciphers pathogenic regulatory genetic variants in the noncoding regions of the human genome. A study published today in Science illustrates how this deep...Read more


GeneDx Publishes Pioneering Vision for Applying AI to Genomics to Improve and Expedite Diagnosis of Genetic Disease at Scale

May 22
Last Trade: 85.69 -5.92 -6.46

Company deploying AI to scale industry-leading rare disease dataset to diagnose growing number of patients with genetic disease, published in the American Journal of Medical Genetics GAITHERSBURG, Md. / May 22, 2025 / Business Wire / GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the publication of a new article in the American Journal of Medical Genetics, demonstrating...Read more


Warby Parker Partners with Google To Develop Intelligent Eyewear

May 20
Last Trade: 21.43 -0.72 -3.25

AI-Powered Glasses Will Be Designed for All-Day Wear Announcement Marks First Eyewear Partnership for Android XR Google Commits Up to $150M, Including an Equity Investment in Warby Parker, as Part of Long-Term Commitment to Partnership NEW YORK / May 20, 2025 / Business Wire / Warby Parker Inc. (NYSE: WRBY) (the “Company”), a direct-to-consumer lifestyle brand focused on vision for all, today announced a partnership with Google to...Read more


Mobile-health Network Solutions Signs MOU to Add AI-enabled Dental Scans and Oral Health Screening to its Telemedicine Platform

Singapore, Singapore--(Newsfile Corp. - May 20, 2025) - Mobile-health Network Solutions (Nasdaq: MNDR) ("MNDR" or "the Company"), a leading MedTech innovator ranked among Asia-Pacific's high-growth companies, today unveiled a new tele-dentistry service that is soon expected to let patients perform an AI-enhanced dental scan at home using the Company's MaNaDr telemedicine app, with expert-reviewed reports delivered within 24 hours. The...Read more


PharmAla Biotech Launches Phenesafe AI Drug Discovery Platform for Novel Phenethylamines

May 15
Last Trade: 0.10 -0.01 -9.09

TORONTO, May 15, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is thrilled to formally announce the launch of the Phenesafe AI platform, an AI technology stack specifically designed to derive novel substituted phenethylamine...Read more


GE HealthCare launches CleaRecon DL, introducing AI-based 3D reconstruction to the interventional suite

May 15
Last Trade: 74.70 -1.37 -1.80

CleaRecon DL receives 510(k) clearance and CE mark, paving the way for clinicians to use 3D image guidance technologies to their full potential with the goal of achieving better clinical and operational outcomes AI-driven solution advances image quality and improves clinical confidence, encouraging adoption of cone-beam computed tomography CHICAGO / May 15, 2025 / Business Wire / GE HealthCare (Nasdaq: GEHC) today announced the launch...Read more


Renovaro Launches Augusta, an AI-Powered Precision Neurology Platform

May 14
Last Trade: 0.29 0.0011 0.38

New Proprietary Target Discovery and Validation Platform Integrates Multiomics, Contingent AI, Phenoclustering, and CRISPR Screens to Accelerate Drug Discovery LOS ANGELES, May 14, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), an AI-driven precision medicine company that leverages AI/ML platforms to improve outcomes for cancer and neurologically challenged patients, today announced it has launched Augusta, a Precision...Read more


Lifeward Completes Research Program with Israeli Human-Robot Interaction Consortium to Integrate Artificial Intelligence and Exoskeletons

May 8
Last Trade: 0.65 -0.02 -2.69

MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, May 08, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, announced the Company has completed its research program as part of the Israel Innovation Authority’s MAGNET incentive program, the Human Robot Interaction Consortium (the “HRI...Read more


Alzamend Neuro Partners with QMENTA, to Advance AI-Powered Imaging for its Phase II Clinical Trial of AL001 Study to Take Place at Massachusetts General Hospital

Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in healthy subjects ATLANTA, May 07, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder...Read more


WELLSTAR Technologies Launches Nexus AI: A Transformative AI Platform for Canadian Healthcare Providers

WELL Health subsidiary WELLSTAR launches Nexus AI™, an AI platform that provides next-generation ambient scribe capabilities with a reimagined user experience. It has been built to serve as the hub for expanding automated AI and agentic capabilities, including disease detection, medical coding, billing automation, and other clinical decision support. This release builds on the success of WELLSTAR’s first generation AI Scribe with...Read more


Recursion to Participate in Upcoming Investor Conferences

Salt Lake City, May 06, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its participation in the following upcoming investor conferences: Bank of America 2025 Health Care Conference — Tuesday, May 13, 2025 JP Morgan Global Technology, Media and Communications Conference — Thursday, May 15, 2025 Webcasts may be found in the...Read more


Tempus AI Announces Notetaker, its AI-Powered Clinical Assistant for Psychiatry

CHICAGO / May 05, 2025 / Business Wire / Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, has announced the launch of Notetaker, an AI-powered clinical assistant to aid psychiatrists in generating progress notes. Notetaker, which is available in Tempus Hub, ambiently records patient sessions to generate transcripts and clinical notes that can be seamlessly stored...Read more


Recursion Reports First Quarter 2025 Financial Results and Provides Business Update

Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing 3 clinical programs and 1 preclinical program following a strategic, data-driven review Partnerships: Achieved fourth milestone in Sanofi collaboration, generating $7 million for an orally active small-molecule lead with best-in-class...Read more


Recursion: Preliminary Phase 1b/2 Data for REC-4881 in Familial Adenomatous Polyposis (FAP) Demonstrates Reduced Polyp Burden

May 4
Last Trade: 4.92 -0.35 -6.64

In the Phase 2 open-label study, REC-4881 (4 mg QD) led to a median 43% reduction (n=6 patients) in polyp burden at the Week 13 assessment at time of data cutoff. Five of six patients (83%) experienced reductions in polyp burden ranging from 31% to 82%, however, one patient showed a substantial increase from baseline. At Week 13, 50% of patients (3 out of 6) achieved ≥1-point improvement in Spigelman stage, a measure of upper GI...Read more


iRhythm Technologies Launches Zio® Long-Term Continuous Monitoring Service in Japan as the Zio® ECG Recording and Analysis System, Advancing AI-Powered Arrhythmia Detection

May 1
Last Trade: 139.89 -2.58 -1.81

iRhythm Zio® Long-Term Continuous Monitoring (LTCM) system — commercially introduced in Japan as the Zio® ECG Recording and Analysis System — brings AI-powered, continuous, uninterrupted ECG monitoring for up to 14 days to Japan Launch is timely amid a growing demand for early, accurate detection of arrhythmias in Japan, the second largest ambulatory cardiac monitoring market in the world, where the prevalence is expected to rise...Read more


Rein Therapeutics and Qureight Announce Planned Integration of Deep-Learning Platform for Phase 2 Trial of LTI-03 in Patients with IPF

May 1
Last Trade: 1.51 0.00 0.00

AUSTIN, Texas, May 1, 2025 /PRNewswire/ -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, and Qureight Ltd, a Core Imaging Laboratory developing deep-learning image analytics, today announced a collaboration for the integration of Qureight's deep-learning platform into...Read more


Health Catalyst Announces Strategic Partnership with Microsoft to Accelerate AI Adoption and Transformation for Care Delivery Organizations

April 29
Last Trade: 3.91 -0.15 -3.69

Health Catalyst's Improvement Expertise Built on Microsoft Azure and Azure AI Foundry to Drive Reliable Insight and Sustained Outcomes for Care Providers SALT LAKE CITY, April 29, 2025 /PRNewswire/ -- Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced a strategic partnership with Microsoft to help healthcare...Read more


Veeva Systems Announcing Veeva AI

April 29
Last Trade: 282.86 -1.43 -0.50

Major new initiative will add AI to Veeva applications and the Veeva Vault Platform to help automate critical industry-specific functions and improve productivity from clinical to commercial PLEASANTON, Calif., April 29, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced Veeva AI, a major new initiative that adds AI to the Veeva Vault Platform and Veeva applications to help life sciences companies automate tasks and...Read more


Tempus AI Introduces Loop, an AI-Powered Target Discovery and Validation Platform

April 28
Last Trade: 58.10 -2.88 -4.72

The new, proprietary target discovery platform integrates RWD, human biological modeling, and CRISPR screens to accelerate novel target identification CHICAGO / Apr 28, 2025 / Business Wire / Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced Tempus Loop, a new oncology-focused platform for target discovery and validation. Loop is Tempus’...Read more


Recursion to Report First Quarter 2025 Business Updates and Financial Results on May 5th

Salt Lake City, UT, April 28, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide business updates and report its first quarter 2025 financial results on Monday, May 5, 2025, before the open of the financial markets. Recursion will host a (L)earnings Call on May 5, 2025 at 8:00 am ET / 6:00 am MT / 1:00 pm GMT. The company...Read more


Waystar Launches New Generative AI and Advanced Automation Across Its Software Platform to Address Billions in Administrative Waste

April 23
Last Trade: 38.64 -0.71 -1.80

AltitudeAI™ expansion accelerates mission-critical claim processes from days to minutes — unlocking major efficiency gains for providers LEHI, Utah, and LOUISVILLE, Ky., April 23, 2025 /PRNewswire/ -- Waystar (Nasdaq: WAY), a provider of leading healthcare payment software, will host an Innovation Showcase today at 2 p.m. ET. At the event, Waystar will unveil numerous new innovations spanning its software platform, including...Read more


Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025

Salt Lake City, UT, April 22, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, will present preliminary data during the 2025 Digestive Disease Week (DDW) meeting from its ongoing Phase 1b/2 clinical trial, TUPELO, which is evaluating the safety and preliminary activity of REC-4881 for the treatment of familial adenomatous polyposis (FAP). The data will...Read more


Ainos and ugo Complete First Robotic Smell Integration in Japan

April 21
Last Trade: 3.23 -0.06 -1.82

Milestone Ignites a New Era of Smell-Enabled Robotics Installs AI Nose in ugo Robot; Real-World Pilots to Begin in Weeks SAN DIEGO, CA / ACCESS Newswire / April 21, 2025 / Ainos, Inc. (Nasdaq:AIMD) (Nasdaq:AIMDW) ("Ainos"), a leader in AI-powered scent digitization, has successfully installed its proprietary AI Nose olfaction module on a humanoid robot developed by ugo, Inc. ("ugo"), Japan's top service robotics company. Completed...Read more


HealthVerity Partners with Recursion to Enhance Clinical Trial Analytics with Real-World Data

April 16
Last Trade: 4.92 -0.35 -6.64

PHILADELPHIA, April 16, 2025 /PRNewswire/ -- HealthVerity, the leader in real-world data (RWD) technology and privacy-compliant data exchange, today announced that Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, has licensed its real-world data to enhance clinical trial design and analytics. Through this agreement, Recursion will integrate HealthVerity de-identified data for...Read more


Hyperfine Enrolls Initial Patients in NEURO PMR Study to Evaluate Use of AI-Powered Portable MRI in Neurology Offices

April 15
Last Trade: 0.77 -0.03 -4.00

Real-world study will assess clinical utility and patient experience across diverse neurological conditions to support adoption of AI-powered portable MRI systems in the office setting. GUILFORD, Conn. / Apr 15, 2025 / Business Wire / Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging...Read more


Illumina and Tempus AI partner to drive the future of precision medicine through genomic AI innovation

April 15
Last Trade: 97.20 -3.61 -3.58

Collaboration accelerates insights on clinical benefits of molecular profiling across all major categories of disease SAN DIEGO and CHICAGO, April 15, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) and Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration to accelerate clinical adoption of next-generation sequencing tests...Read more


FDA Clears Ceribell’s Clarity™ Algorithm for Pediatric Patients, Making Ceribell the First and Only FDA-Cleared AI Technology for Detection of Electrographic Seizures in Patients Ages 1 Year and Older

April 15
Last Trade: 17.25 -1.68 -8.87

SUNNYVALE, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its next generation Ceribell Clarity™ algorithm for the detection of electrographic seizures in patients ages 1...Read more


ReShape Lifesciences Partners with Motion Informatics to Bring AI-Driven Neurorehabilitation Technology to the U.S. Market

April 9
Last Trade: 2.36 -0.008 -0.34

IRVINE, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that it has signed an agreement with Haifa, Israel-based Motion Informatics to exclusively import and distribute their next-generation neuromuscular rehabilitation devices in the U.S. The flagship product, the Stimel-03, was showcased at the American...Read more


Renovaro and BioSymetrics Close Merger to Accelerate AI-Driven Biomarker Discovery and Precision Medicine

Strategic Combination Intended to Drive Advanced AI-Driven Drug Development and Expand Precision Medicine Applications Across Cancer and Neurology LOS ANGELES, April 09, 2025 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ: RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced it closed its previously announced merger transaction with...Read more


Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries

April 9
Last Trade: 4.92 -0.35 -6.64

Kyiv, Ukraine and Salt Lake City, UT, April 09, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced the generation of screening libraries leveraging tools within its AI/ML platform, the Recursion OS, with Enamine's REAL Space, the world’s largest source of make-on-demand small molecules. Together, the two companies have curated 10 enriched...Read more


Recursion Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas

April 8
Last Trade: 4.92 -0.35 -6.64

Salt Lake City, UT, April 08, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that the first patient has been dosed in the Phase 1 EXCELERIZE clinical study evaluating REC-3565 for the treatment of relapsed or refractory B-cell lymphomas. "REC-3565 showed durable tumor regressions in preclinical studies, both as a monotherapy and in...Read more


Conduit Pharmaceuticals Expands Partnership with Sarborg to Leverage Machine Learning Data Analysis for Pipeline Optimization

April 7
Last Trade: 2.43 -0.50 -16.95

Conduit expands its partnership with Sarborg to apply advanced machine learning-driven analysis on clinical data from its AstraZeneca-acquired assets, aiming to uncover new insights and optimize development pathways. NAPLES, Fla. and CAMBRIDGE, United Kingdom, April 07, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit Pharmaceuticals" or "Conduit" or the “Company”) today announces that it has entered into...Read more


NetraMark And Worldwide Clinical Trials Announce Agreement To Transform Clinical Trial Design With AI-Powered Precision

April 3
Last Trade: 1.32 -0.03 -2.22

TORONTO, April 3, 2025 /PRNewswire/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is transforming clinical trials with AI powered precision analytics in the pharmaceutical industry, today announced a global agreement with Worldwide Clinical Trials ("Worldwide"), a full-service, global contract research organization (CRO)....Read more


Recursion to Participate in Upcoming Investor Conference

Salt Lake City, UT, April 01, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today its participation in the following upcoming investor conference: Needham 24th Annual Virtual Healthcare Conference — Monday, April 7, 2025 Webcasts may be found in the events section of the Recursion Investor Relations website at...Read more


HEALWELL AI Completes Acquisition of Orion Health, Becoming a Global Leader in Healthcare Data Interoperability and Artificial Intelligence

April 1
Last Trade: 1.31 -0.01 -0.76

HEALWELL has acquired Auckland, New Zealand-based Orion Health Holdings Limited ("Orion Health"), a global healthcare intelligence platform providing subscription licenses and services to marquee public sector clients with data interoperability and healthcare navigation products. Orion Health1 has approximately 400 employees with offices in 11 countries globally. Its software solutions currently support over 70 public and private...Read more


Alpine ENT Expands Partnership with CareCloud, Implements FrontDesk Assist to Enhance Patient Experience

March 26
Last Trade: 2.35 -0.12 -4.67

SOMERSET, N.J., March 26, 2025 (GLOBE NEWSWIRE) -- CareCloud, Inc. (the “Company”) (Nasdaq: CCLD, CCLDO), a leading provider of healthcare technology and AI-powered revenue cycle management (RCM) solutions, today announced the expanded adoption of its services by Alpine Ear, Nose & Throat PC, a premier otolaryngology group based in Colorado. Following a successful RCM engagement, Alpine ENT has now implemented CareCloud FrontDesk...Read more


Charles River Laboratories and Valo Health Identify a Potential Therapeutic for Lupus Using Logica®, an AI-Powered Drug Discovery Platform

March 25
Last Trade: 153.06 -4.06 -2.58

First Logica-identified candidate marks a progression-based milestone in ongoing partnership with Pioneering Medicines, Flagship Pioneering’s in-house drug development unit WILMINGTON, Mass. & CAMBRIDGE, Mass. / Mar 25, 2025 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) and Valo Health, Inc. today announced the identification of an advanceable product candidate for the treatment of different forms of...Read more


Anixa Biosciences Enters Letter of Intent with VERDI Solutions to Develop Artificial Intelligence-Guided Personalized and Off-the-Shelf Cancer Vaccines

March 25
Last Trade: 3.21 -0.09 -2.73

VERDI's personalized vaccines have demonstrated safety and efficacy in cancer patients SAN JOSE, Calif., March 25, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has entered into a letter of intent with VERDI Solutions, GmbH to develop personalized and off-the-shelf peptide vaccines for cancer...Read more


Predictive Oncology Successfully Develops Predictive Models Derived from Never-Before-Seen Compounds for Prevalent Cancer Indications Including Breast, Colon and Ovary

March 25
Last Trade: 0.83 -0.02 -2.36

Company successfully developed predictive models derived from 21 unique compounds from the Natural Products Discovery Core at the University of Michigan Tumor response models for novel compounds represent true drug discovery using Predictive's active machine learning platform PITTSBURGH, March 25, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, announced today that it has...Read more


Optimind Pharma Enters into Letter of Intent with Monjin to Acquire AI Business

March 24
Last Trade: 0.01 0.00 0.00

Toronto, Ontario--(Newsfile Corp. - March 24, 2025) - Optimind Pharma Corp. (CSE: OMND) (the "Optimind" or the "Company") announces that it has entered into a non-binding letter of intent dated March 18, 2025, (the "LOI") to acquire all of the issued and outstanding shares (the "Transaction") of Monjin Interviews Private Limited ("Monjin"), a corporation formed under the laws of India. The Transaction is an arm's length...Read more


Ventripoint Diagnostics Publishes Whitepaper on the Use of AI in Whole-Heart Analysis

March 24
Last Trade: 0.13 0.005 4.00

Toronto, Ontario – TheNewswire - March 24, 2025 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT; OTC:VPTDF) is pleased to announce the release of a whitepaper comparing the performance of the VMS+™4.0 advanced Automated Radiological Image Processing Software/System to the previous basic model, VMS+ 3.0. This latest advancement of Ventripoint’s proprietary technology, VMS+ 4.0, which recently received U.S. FDA...Read more


GE HealthCare launches AI-driven, patient-friendly Invenia ABUS Premium to accelerate scanning and drive early cancer detection in dense breasts

March 20
Last Trade: 74.70 -1.37 -1.80

The latest Invenia ABUS is designed to deliver optimal outcomes with its innovative, patient-friendly, and efficient AI-driven technology Invenia ABUS Premium features new integrated Verisound AI and AI Assistant, which ensure faster and reproducible scanning and reading with extraordinary image quality The non-invasive ultrasound technology, equipped with a novel Reverse Curve transducer and separate acquisition and reading...Read more


ICON Becomes the First Large Clinical Research Organization to Fully Integrate Medidata Clinical Data Studio, Streamlining Data Management and Review

March 20
Last Trade: 147.37 -2.73 -1.82

Adoption allows ICON to take full advantage of the Medidata “Data Experience,” leveraging AI to unify data sources, standardize outputs, and reduce reconciliation efforts NEW YORK / Mar 20, 2025 / Business Wire / Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced that ICON plc, (NASDAQ: ICLR) a world-leading clinical research organization (CRO) powered by...Read more


Quest Diagnostics to Collaborate with Google Cloud to Streamline Data and Personalize Customer Experiences Using Generative AI

March 18
Last Trade: 173.49 -3.43 -1.94

SUNNYVALE, Calif. and SECAUCUS, N.J., March 18, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced a collaboration with Google Cloud to streamline Quest's data management, improve data analytics, and personalize the experiences Quest delivers to patients, providers and other customers. To do so, Quest Diagnostics will use Google Cloud's data analytics and generative AI (gen...Read more


Hyperfine and NVIDIA Collaborate to Revolutionize Neuroimaging with AI-Powered Innovation

March 17
Last Trade: 0.77 -0.03 -4.00

Collaboration aims to make portable MRI faster, smarter, and more accessible worldwide. GUILFORD, Conn. / Mar 17, 2025 / Business Wire / Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced a strategic collaboration with NVIDIA. This collaboration...Read more


Partex and Fortress Biotech Announce Strategic Collaboration to Accelerate Asset Identification and Evaluation Using Proprietary AI Platform

March 17
Last Trade: 1.86 -0.03 -1.33

FRANKFURT, Germany and MIAMI, March 17, 2025 (GLOBE NEWSWIRE) -- Partex NV and Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company, today announced a strategic collaboration aimed at identifying and evaluating biopharmaceutical compounds using artificial intelligence (AI) for potential acquisition or licensing by Fortress. Partex will deploy its proprietary AI-based drug discovery and development...Read more


Perimeter Medical Imaging AI Files FDA PMA Application for its Next-Generation B-Series OCT with ImgAssist AI 2.0

March 17
Last Trade: 0.27 0.005 1.92

TORONTO and DALLAS, March 17, 2025 /CNW/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PYNKF) ("Perimeter" or the "Company"), a commercial-stage medical technology company, today announced the submission of a Premarket Approval ("PMA") application to the U.S. Food and Drug Administration ("FDA") for the Company's next-generation Perimeter B-Series OCT system, which combines proprietary artificial intelligence ("AI")...Read more


Spectral AI Announces Successful Results from its Burn Validation Study of the DeepView System

March 17
Last Trade: 2.70 0.02 0.75

DeepView® System outperforms burn physicians in identifying non-healing tissue Landmark Burn Validation Study, one of the largest in U.S. history, confirms DeepView’s performance Spectral AI plans FDA submission by mid-2025, targeting De Novo Clearance and rapid commercialization to transform burn care DALLAS, March 17, 2025 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ: MDAI) (“Spectral AI” or the “Company”), developer of the AI-driven...Read more


GeneDx Enhances the Power of its Interpretation Platform with Artificial Intelligence (AI) Powered Gene Ranker to Enable Faster and More Efficient Clinical Analysis

March 13
Last Trade: 85.69 -5.92 -6.46

GeneDx's Multiscore tool to be showcased at the American College of Medical Genetics and Genomics (ACMG) Annual Meeting GAITHERSBURG, Md. / Mar 13, 2025 / Business Wire / GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced Multiscore, an advanced AI-powered decision support tool designed to revolutionize genetic analysis by improving diagnostic efficiency, streamlining...Read more


MeiraGTx Enters into a Strategic Collaboration with Hologen AI to Expedite Phase 3 Development of AAV-GAD for Parkinson’s Disease and Industrialize MeiraGTx’s Proprietary Manufacturing Process

March 13
Last Trade: 7.75 0.24 3.20

MeiraGTx to receive $200 million in upfront cash consideration MeiraGTx and Hologen will form a joint venture, Hologen Neuro AI Ltd, with an additional $230 million committed capital from Hologen to fund 100% of the development of AAV-GAD for Parkinson’s disease through to commercialization, as well as other potential pipeline products MeiraGTx will enter into clinical and commercial supply agreements with Hologen Neuro AI Ltd to...Read more


Next-Gen Cancer Treatment: Rakovina Therapeutics’ AI-Driven ATR Inhibitors Enter Preclinical Testing

March 12
Last Trade: 0.73 -0.07 -8.75

VANCOUVER, British Columbia, March 12, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV)(FSE: 7JO), a biopharmaceutical company advancing innovative cancer therapies through artificial intelligence (AI)-powered drug discovery, announced today that the company has received the first synthesized batch of AI-generated ATR inhibitor compounds developed in collaboration with Variational AI. This milestone marks a significant...Read more


Tempus Announces Acquisition of Deep 6 AI

March 11
Last Trade: 58.10 -2.88 -4.72

Deep 6 is integrated with over 750 provider site locations spanning more than 30 million patients, which will materially add to Tempus’ existing network CHICAGO / Mar 11, 2025 / Business Wire / Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has acquired Deep 6 AI, a leading AI-powered precision research platform for healthcare...Read more


Ainos and ASE Partner to Power AI Scent Digitization in Semiconductor Manufacturing

March 11
Last Trade: 3.23 -0.06 -1.82

Harnessing AI-Powered Scent Digitization for Smarter, Safer, and More Sustainable Factories With this collaboration, Ainos takes a major step in its mission to digitize scent - expanding its expertise from healthcare applications to industrial automation. AI Nose, originally developed for volatile organic compound (VOC) detection in medical diagnostics, is now expanding to smart factories. By unlocking insights from invisible...Read more


Hemostemix and FireFly Neuroscience's Brain Network Analytics (BNA(TM)) Engage to Complete Phase 1 Vascular Dementia Clinical Trial of ACP-01

March 6
Last Trade: 0.15 0.00 0.00

A growing body of clinical evidence supports the use of Firefly's FDA-Cleared BNA(TM) platform to study ACP-01 as a treatment for vascular dementia Calgary, Alberta--(Newsfile Corp. - March 6, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or "HEM"), an autologous angiogenic stem cell company that has safely treated 498 patients for various forms of cardiovascular disease, including vascular...Read more


PainReform Completes Strategic Acquisition of DeepSolar, Unlocking New Growth Opportunities in AI-Driven Solar Analytics

March 5
Last Trade: 1.42 0.02 1.07

TEL AVIV, Israel, March 05, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced the successful closing of its previously announced acquisition of 100% of the business activity of DeepSolar, an AI-driven solar analytics platform, from BladeRanger Ltd, a public company registered...Read more


Lisata Therapeutics and GATC Health Consummate First Step in Strategic Collaboration to use AI to Derisk and Accelerate Drug Development

March 5
Last Trade: 2.58 -0.04 -1.53

Strategic collaboration harnesses GATC’s proprietary Artificial Intelligence-powered, validated Multiomics Advanced Technology™ platform to rapidly optimize and derisk drug discovery and development, thereby accelerating and economizing the traditional drug development process. Lisata’s investigational product, certepetide, to be the subject of a comprehensive AI-analysis to determine optimum disease targets and development...Read more


IGC Pharma Expands AI Platform With Advanced Diagnostic Model for Alzheimer's and Dementia Detection

March 4
Last Trade: 0.32 0.02 6.12

POTOMAC, MD / ACCESS Newswire / March 4, 2025 / IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American:IGC) today announced an advancement in its Artificial Intelligence ("AI") platform with the development of a new AI-driven model designed to improve the diagnosis of Alzheimer's disease (AD) and other causes of dementia. With Alzheimer's accounting for approximately 60-80% of all dementia cases, alongside other conditions such as...Read more


Clover Health: Counterpart Health Partners with Google Cloud to Improve Clinical Data Access for Physicians

WILMINGTON, Del., March 03, 2025 (GLOBE NEWSWIRE) -- Counterpart Health, Inc. (“Counterpart”), a leading AI-powered physician enablement platform, today announced it has partnered with Google Cloud to integrate Vertex AI Search into its flagship technology, Counterpart Assistant. This innovation gives providers on Counterpart Assistant a generative AI (gen AI) search experience across the breadth of a patient’s digital health record to...Read more


IDEAYA Biosciences Announces Collaboration with ATTMOS to Accelerate AI/ML-Enabled Drug Discovery for Unprecedented First-in-Class Oncology Targets

March 3
Last Trade: 21.27 -0.83 -3.76

SOUTH SAN FRANCISCO, Calif., March 3, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced a research collaboration with ATTMOS as part of its efforts to build a physics-based computational small molecule discovery platform that rapidly unlocks what are currently perceived as undruggable oncology...Read more


Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results

February 28
Last Trade: 4.92 -0.35 -6.64

Reported promising safety and preliminary efficacy data for REC-617, an oral CDK7 inhibitor, and met primary endpoints and demonstrated encouraging trends in efficacy for REC-994 in cerebral cavernous malformations Advanced three new clinical studies across oncology, rare disease, and recurrent C. diff infection with REC-1245, REC-4881, and REC-3964 Delivered milestones for partners including the first neuro-phenomap for Roche and...Read more


Rakovina Therapeutics and Variational AI Strengthen Partnership

February 26
Last Trade: 0.73 -0.07 -8.75

VANCOUVER, British Columbia, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing cancer therapies based on DNA-damage response technologies, proudly reaffirms its strategic partnership with Variational AI. This announcement comes on the heels of Variational AI’s impressive $5.5 million oversubscribed financing round, led by Nimbus Synergies with participation from...Read more


ImmunoPrecise Antibodies and RIBOPRO Partner to Advance mRNA-Driven Antibody Discovery, Unlocking New Frontiers in Immunotherapy

February 26
Last Trade: 1.58 0.27 20.61

AUSTIN, Texas / Feb 26, 2025 / Business Wire / ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), a global leader in AI-powered antibody discovery and development, today announced a strategic collaboration with RIBOPRO, a pioneering technology provider specializing in mRNA and lipid nanoparticle (LNP) technologies. This collaboration seeks to revolutionize the discovery and development of therapeutic antibodies by...Read more


HEALWELL AI's VeroSource Unveils Digital Twin Technology to Bring Real-Time Intelligence to Healthcare Management

February 26
Last Trade: 1.31 -0.01 -0.76

VeroSource to support cutting edge Digital Twin technology on its VS Data-as-a-Service Platform, delivering real-time insights and advanced data visualization to optimize healthcare operations. A Digital Twin is a virtual model of a healthcare system or facility that provides real-time insights for better decision-making. By simulating operations without disruption, this technology allows healthcare managers to optimize efficiency,...Read more


RadNet: DeepHealth Introduces New AI-Powered Radiology Informatics and Population Screening Solutions at #ECR2025

February 26
Last Trade: 55.52 -0.69 -1.23

At ECR 2025, DeepHealth will introduce new AI-powered radiology informatics and cancer screening solutions enabled by DeepHealth OS, its pioneering cloud-native operating system, to address clinical and operational challenges. DeepHealth aims to bring to European customers its Diagnostic Suite™ to redefine the traditional Picture Archiving and Communication System (PACS) with a unified workspace tailored for modern radiology, and...Read more


Netramark And The Ontario Brain Institute Partner To Advance AI-Powered Neuroanalytics For Major Depression Research

February 25
Last Trade: 1.32 -0.03 -2.22

TORONTO, Feb. 25, 2025 /CNW/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: 8TV) a generative AI software leader in clinical trial analytics, announces its funded collaboration with the Ontario Brain Institute (OBI) to enhance the analysis of brain imaging and multi-modal data from Major Depressive Disorder (MDD) clinical research to achieve treatment separation in...Read more


RadNet’s Wholly-Owned Subsidiary, DeepHealth, and ConcertAI’s TeraRecon Announce Strategic Collaboration Around Integrated AI and Advanced Visualization

February 25
Last Trade: 55.52 -0.69 -1.23

DeepHealth’s cloud-native Diagnostic Suite™ will integrate TeraRecon’s SaaS-based advanced visualization capabilities, creating a unified AI-powered diagnostic workspace that enhances workflows and expands access to advanced diagnostic tools across diverse healthcare settings. The collaboration will also integrate DeepHealth’s clinical AI solutions into TeraRecon’s AI ecosystem, augmenting its capabilities and expanding its impact in...Read more


Myriad Genetics Partners with PATHOMIQ to add Artificial Intelligence Technology Platform to its Oncology Portfolio

February 24
Last Trade: 5.38 -0.22 -3.93

SALT LAKE CITY, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, and PATHOMIQ, Inc., a developer of artificial intelligence (AI)-enabled prognostic and predictive tests for advancing access to personalized medicine and empowering treatment decisions, announced that they have entered into a strategic collaboration for Myriad to exclusively license...Read more


Recursion to Report Fourth Quarter and Fiscal Year 2024 Business Updates and Financial Results on February 28th

Salt Lake City, UT, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today it will provide business updates and report its fourth quarter and full year 2024 financial results on Friday, February 28, 2025, before the open of the financial markets. Recursion will host a (L)earnings Call on February 28, 2025 at 8:30 am ET / 6:30...Read more


HEALWELL AI's Khure Health Provides Update Highlighting Significant Acceleration in User and Life Sciences Partner Adoption of Disease Detection AI Powered Co-Pilots and Strong Physician NPS Scores

February 24
Last Trade: 1.31 -0.01 -0.76

In Q4-2024, HEALWELL's subsidiary, Khure Health ("Khure") helped physicians identify over 43,000 high-risk patients with its AI-Powered Physician Co-Pilots, across 8 clinical specialities harnessing 132 disease specific algorithms. This figure reflected a quarter over quarter sequential growth of 22% as compared to Q3-2024 and year-over-year growth of 500% as compared to Q4-2023. HEALWELL has executed 4 new Master Services Agreements...Read more


Incyte and Genesis Therapeutics Announce Strategic AI-focused Research Collaboration

February 20
Last Trade: 67.39 -1.06 -1.55

Incyte and Genesis will leverage Genesis’ GEMS artificial intelligence (AI) platform to unlock the discovery of breakthrough small molecule therapeutics against Incyte-selected targets Incyte receives exclusive rights to develop and commercialize collaboration products WILMINGTON, Del. & BURLINGAME, Calif. / Feb 20, 2025 / Business Wire / Incyte (Nasdaq:INCY) and Genesis Therapeutics, Inc. announced today that the companies have...Read more


Conduit Pharmaceuticals Progresses Phase II of its AI Initiative with Sarborg

February 20
Last Trade: 2.43 -0.50 -16.95

Collaboration reinforces Conduit’s commitment to leveraging AI and cybernetics to reduce human error, lower costs, and accelerate timelines in drug development Sarborg delivers a prototype AI-product to Conduit’s Management team NAPLES, Fla. and CAMBRIDGE, United Kingdom, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), is pleased to announce the completion of the initial...Read more


Altitude Lab Launches Pre-Seed Venture Fund, Anchored by Recursion CEO Chris Gibson, Enabling SBIR-awarded Biotechs Hit by Funding Gap to Build in Salt Lake City

February 19
Last Trade: 4.92 -0.35 -6.64

SALT LAKE CITY, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Altitude Lab, a biotech accelerator started by Recursion in Salt Lake City, today announced the launch of its pre-seed venture fund aimed at supporting early-stage biotechnology startups impacted by recent federal funding policy shifts. Together with Altitude Lab, Altitude Lab Fund intends to provide crucial capital, lab space, and mentorship to promising Small Business Innovation Research...Read more


PainReform Executes Definitive Agreement to Acquire DeepSolar, Marking a Unique Expansion Opportunity

DeepSolar brings new customer base in creation, including major utility-scale solar operators and independent power producers, while breaking into the residential solar market The Company remains committed to advancing its drug delivery technologies while broadening its growth potential TEL AVIV, Israel, Feb. 18, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty...Read more


Predictive Oncology Reports Positive Results Utilizing Artificial Intelligence for Drug Repurposing

February 18
Last Trade: 0.83 -0.02 -2.36

Company successfully identified several abandoned or discontinued drugs for further testing and development in ovarian and other cancer types Creates significant business development opportunities with meaningful long-term commercial potential with large pharmaceutical companies PITTSBURGH, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, today provided an...Read more


Sign Up To Get Daily
Life Science News

Please review our Disclaimer and Privacy Policy before subscribing.

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE